Table 2.

The basic characteristics of the excluded published articles and participants.

Study ID	Study duration	Reason of exclusion	Study arms	N	Main results
Jayne 2012[26]	52 weeks	- Open-label extension study of previous 5 clinical trials. - Had no placebo arm.	Flibanserin 50–100 mg/d	1723	- Somnolence, sedation, fatigue, dizziness, nausea, and vomiting were reported by 15.8%, 1.6%, 7.6%, 6.9%, 6.3%, and 1.4% of participants, respectively. - At study end, 42% of baseline non-remitters had improved their FSFI score to remission level.

FSFI = Female Sexual Function Index.